Lessons from Cancer Immunoediting in Cutaneous Melanoma

Overview

Journal Clin Dev Immunol

Specialty Allergy & Immunology

Date 2012 Aug 28

PMID 22924051

Citations 13

Authors

Mariana Aris

Maria Marcela Barrio

Jose Mordoh

Affiliations

Soon will be listed here.

Abstract

We will revisit the dual role of the immune system in controlling and enabling tumor progression, known as cancer immunoediting. We will go through the different phases of this phenomenon, exposing the most relevant evidences obtained from experimental models and human clinical data, with special focus on Cutaneous Melanoma, an immunogenic tumor per excellence. We will describe the different immunotherapeutic strategies employed and consider current models accounting for tumor heterogeneity. And finally, we will propose a rational discussion of the progress made and the future challenges in the therapeutics of Cutaneous Melanoma, taking into consideration that tumor evolution is the resulting from a continuous feedback between tumor cells and their environment, and that different combinatorial therapeutic approaches can be implemented according to the tumor stage.

Citing Articles

Tumor: Stroma Interaction and Cancer.

Rogers M, Mi Z, Li N, Wai P, Kuo P Exp Suppl. 2022; 113:59-87.

PMID: 35165860 DOI: 10.1007/978-3-030-91311-3_2.

Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells.

Tucci M, Passarelli A, Mannavola F, Felici C, Stucci L, Cives M Front Oncol. 2019; 9:1148.

PMID: 31750245 PMC: 6848379. DOI: 10.3389/fonc.2019.01148.

PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab.

Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D Oncoimmunology. 2018; 7(12):e1405206.

PMID: 30524879 PMC: 6279420. DOI: 10.1080/2162402X.2017.1405206.

The novel immunoglobulin super family receptor SLAMF9 identified in TAM of murine and human melanoma influences pro-inflammatory cytokine secretion and migration.

Dollt C, Michel J, Kloss L, Melchers S, Schledzewski K, Becker K Cell Death Dis. 2018; 9(10):939.

PMID: 30232321 PMC: 6145869. DOI: 10.1038/s41419-018-1011-1.

Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma.

Aris M, Mordoh J, Barrio M Front Immunol. 2017; 8:1024.

PMID: 28970830 PMC: 5609554. DOI: 10.3389/fimmu.2017.01024.

References

Kawakami Y, Eliyahu S, Delgado C, Robbins P, Sakaguchi K, Appella E . Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994; 91(14):6458-62. PMC: 44221. DOI: 10.1073/pnas.91.14.6458. View

Meyer C, Sevko A, Ramacher M, Bazhin A, Falk C, Osen W . Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A. 2011; 108(41):17111-6. PMC: 3193202. DOI: 10.1073/pnas.1108121108. View

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View

Morgan R, Dudley M, Wunderlich J, Hughes M, Yang J, Sherry R . Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796):126-9. PMC: 2267026. DOI: 10.1126/science.1129003. View

Street S, Cretney E, Smyth M . Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood. 2001; 97(1):192-7. DOI: 10.1182/blood.v97.1.192. View

Gerlini G, Urso C, Mariotti G, Di Gennaro P, Palli D, Brandani P . Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol. 2007; 125(2):184-93. DOI: 10.1016/j.clim.2007.07.018. View

Poschke I, Mougiakakos D, Hansson J, Masucci G, Kiessling R . Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010; 70(11):4335-45. DOI: 10.1158/0008-5472.CAN-09-3767. View

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

10.

Schmidt H, Suciu S, Punt C, Gore M, Kruit W, Patel P . Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 2007; 25(12):1562-9. DOI: 10.1200/JCO.2006.09.0274. View

11.

Shields J, Kourtis I, Tomei A, Roberts J, Swartz M . Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science. 2010; 328(5979):749-52. DOI: 10.1126/science.1185837. View

12.

Quintana E, Shackleton M, Sabel M, Fullen D, Johnson T, Morrison S . Efficient tumour formation by single human melanoma cells. Nature. 2008; 456(7222):593-8. PMC: 2597380. DOI: 10.1038/nature07567. View

13.

Koebel C, Vermi W, Swann J, Zerafa N, Rodig S, Old L . Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450(7171):903-7. DOI: 10.1038/nature06309. View

14.

Kaplan D, Shankaran V, Dighe A, STOCKERT E, Aguet M, Old L . Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998; 95(13):7556-61. PMC: 22681. DOI: 10.1073/pnas.95.13.7556. View

15.

Derre L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A . Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol. 2006; 177(5):3100-7. DOI: 10.4049/jimmunol.177.5.3100. View

16.

Kawakami Y, Eliyahu S, Delgado C, Robbins P, Rivoltini L, Topalian S . Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994; 91(9):3515-9. PMC: 43610. DOI: 10.1073/pnas.91.9.3515. View

17.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

18.

Pepe C, Ricci R, Cortelazzi C, Mori G, Zambito F, Campanini N . The vast majority of lymphocytes infiltrating primary cutaneous melanoma express the CD27 costimulatory receptor: implications for melanoma progression. Eur J Dermatol. 2011; 21(2):178-83. DOI: 10.1684/ejd.2010.1240. View

19.

Clark Jr W, Elder D, Guerry 4th D, Braitman L, Trock B, Schultz D . Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81(24):1893-904. DOI: 10.1093/jnci/81.24.1893. View

20.

Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23(10):2346-57. PMC: 1475951. DOI: 10.1200/JCO.2005.00.240. View